List of Excipients in Branded Drug VABOMERE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Melinta Therapeutics LLC	VABOMERE	meropenem-vaborbactam	70842-120	SODIUM CARBONATE	2031-08-29

Vabomere Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Vabomere is an intravenous fixed-dose combination of meropenem and vaborbactam. Its commercial formulation is deliberately simple: the sterile lyophilized powder contains the two active ingredients and sodium carbonate as the principal excipient. The strongest opportunities are not conventional excipient substitution alone. They are improved stability, ready-to-use delivery, reduced preparation burden, pediatric dosing flexibility, and differentiated hospital supply models.

Vabomere's formulation strategy protects a difficult carbapenem-beta-lactamase inhibitor combination while supporting hospital administration. The principal commercial constraint is that any reformulation must preserve meropenem potency, vaborbactam activity, sterility, compatibility with intravenous systems, and the product's established clinical dosing regimen.

What excipients are used in Vabomere?

Vabomere contains meropenem trihydrate, vaborbactam, and sodium carbonate. The product is supplied as a sterile, preservative-free lyophilized powder for intravenous infusion.[1]

Component	Function in Vabomere
Meropenem trihydrate	Carbapenem antibacterial active ingredient
Vaborbactam	Beta-lactamase inhibitor active ingredient
Sodium carbonate	Buffering and formulation-stability excipient
Water for injection	Reconstitution vehicle, supplied separately

The commercial vial contains the equivalent of 1 gram of meropenem and 0.5 gram of vaborbactam. Sodium carbonate provides the formulation's principal pH-control function. The product does not rely on preservatives, surfactants, or complex polymeric stabilizers.[1]

Why is sodium carbonate important?

Meropenem is susceptible to degradation in aqueous solution. Vaborbactam also requires a controlled chemical environment to maintain potency and inhibit relevant serine beta-lactamases. Sodium carbonate helps establish and maintain the alkaline conditions used during manufacture, lyophilization, reconstitution, and dilution.

The excipient has four strategic functions:

1. It supports chemical stability during storage.
2. It helps maintain a suitable pH after reconstitution.
3. It reduces the need for a more complex excipient system.
4. It supports a sterile powder presentation with commercially practical shelf life.

A formulation containing only one principal excipient can reduce raw-material complexity, analytical burden, and supply-chain exposure. It also narrows the number of potential formulation patents available to the innovator.

How does the Vabomere formulation work after reconstitution?

Vabomere is reconstituted and then diluted in 0.9% sodium chloride before intravenous infusion. The label specifies a 3-hour infusion, administered every 8 hours in adults with normal renal function.[1]

The formulation must therefore remain chemically and physically acceptable through several stages:

• Lyophilized storage in the vial.
• Reconstitution by hospital personnel.
• Transfer into an intravenous infusion bag.
• Refrigerated or room-temperature holding before administration.
• A relatively long infusion period.

The label permits defined in-use storage periods for reconstituted and diluted solutions. These conditions create a commercial advantage for hospital pharmacies because the product can be prepared in advance within the validated time window.[1]

What formulation risks must a Vabomere competitor manage?

A competing formulation must address:

• Meropenem hydrolysis in solution.
• Vaborbactam degradation or potency loss.
• pH drift after reconstitution.
• Precipitation or visible particulate formation.
• Adsorption to infusion bags or tubing.
• Compatibility with sodium chloride infusion solutions.
• Sterility throughout the handling period.
• Dose uniformity between the two active ingredients.
• Renal-dose adjustment requirements.

The two-drug combination increases formulation complexity compared with a meropenem-only product. A stabilizer that benefits meropenem could alter vaborbactam stability, pH, osmolality, or infusion compatibility.

What commercial opportunities exist for Vabomere excipients?

The most credible commercial opportunities are delivery and stability improvements rather than replacement of sodium carbonate with a chemically equivalent buffer.

Ready-to-use Vabomere presentations

A ready-to-use or pharmacy-ready bag could reduce compounding steps and lower medication-preparation risk. Potential formats include:

• A premixed intravenous bag.
• A dual-chamber bag separating incompatible components until activation.
• A vial with an integrated diluent system.
• A pharmacy bulk package for controlled hospital preparation.
• A longer-stability concentrated solution for automated compounding.

The commercial value would be greatest in hospitals with high carbapenem utilization, centralized pharmacy operations, and strict sterile-compounding requirements.

A ready-to-use product would require new stability, container-closure, extractables-and-leachables, particulate, sterility, and administration-set data. It could also require a new drug application supplement or a separate regulatory pathway, depending on the extent of formulation and presentation changes.

Extended in-use stability

The current product requires hospital preparation within specified label conditions. A formulation that remains stable for 24 to 72 hours under refrigerated and room-temperature conditions could support:

• Central pharmacy batch preparation.
• Home-infusion programs.
• Outpatient parenteral antimicrobial therapy.
• Hospital-at-home models.
• Reduced product wastage.
• More efficient overnight and weekend dispensing.

Extended stability is particularly valuable for an antibiotic administered every 8 hours. A longer validated hold time could reduce the number of preparation events and improve operational efficiency.

Reduced-volume or higher-concentration formulations

The standard dose requires preparation of a substantial infusion volume. A higher-concentration formulation could reduce:

• Infusion-bag size.
• Fluid burden.
• Nursing handling time.
• Pump occupancy.
• Transportation volume for outpatient use.

The main technical challenge is maintaining solubility and avoiding precipitation at higher concentrations. Any concentration increase would require new compatibility and infusion-rate assessments.

Pediatric and renal-adjustment presentations

Vabomere is approved for adults and pediatric patients 3 months of age and older for specified infections.[1] Pediatric treatment creates an opportunity for more flexible dose preparation, including:

• Lower-strength vials.
• Single-dose pediatric containers.
• Concentrated solutions for small infusion volumes.
• Ready-to-use syringes or minibags.
• Improved dose withdrawal accuracy.

Renal impairment also creates a need for dose-adjusted administration. Presentations that reduce pharmacy calculations could have commercial value, provided they do not create excessive SKU complexity.

What formulation patents could protect a Vabomere reformulation?

A reformulated Vabomere product could generate patentable subject matter in several categories.

Excipient-composition patents

Potential claims could cover:

• Meropenem and vaborbactam with a defined carbonate concentration.
• A specified pH range.
• A stabilizing buffer system.
• A defined osmolality range.
• Particular ratios of active ingredients to excipient.
• A formulation with reduced degradation products.

A simple excipient substitution may have limited patent strength unless it produces an unexpected stability, compatibility, or manufacturing result.

Lyophilization-process patents

Process claims could address:

• Freezing rate.
• Primary and secondary drying conditions.
• Residual-moisture limits.
• Cake structure.
• Reconstitution time.
• Protection against meropenem degradation.
• Control of vaborbactam potency during storage.

Lyophilization patents can create meaningful manufacturing barriers when the active combination is sensitive to moisture, heat, or pH variation.

Container and delivery patents

Potential protection includes:

• Dual-chamber containers.
• Integrated transfer devices.
• Premixed infusion bags.
• Low-sorption polymer bags.
• Light-protective packaging.
• Automated reconstitution systems.
• Container-closure configurations that extend stability.

These rights can be commercially important even when the underlying drug-composition patents are nearing expiration because they may delay adoption of a competing presentation.

Method-of-use and administration patents

Method claims could address:

• Specific infusion durations.
• Dosing in patients with renal impairment.
• Treatment of carbapenem-resistant Enterobacterales.
• Use in pediatric populations.
• Outpatient administration.
• Combination with therapeutic drug monitoring or other antibacterial agents.

The enforceability of method-of-use claims depends on prescribing behavior, labeling, induced infringement evidence, and the degree to which the approved indication is reflected in a generic label.

What is the Orange Book status of Vabomere?

Vabomere is approved under FDA NDA 209776 and is listed as a prescription antibacterial product.[2] The reference product is a combination of meropenem and vaborbactam supplied as an intravenous powder.

Because Vabomere is a small-molecule drug, the principal abbreviated pathway is an ANDA rather than a biosimilar application. The product is not a biologic, and biosimilar concepts do not apply to its regulatory pathway.

The relevant exclusivity layers include:

Exclusivity or protection	Commercial effect
FDA approval exclusivity	Delayed certain abbreviated applications during the applicable period
Qualified Infectious Disease Product status	Five-year extension of applicable exclusivity or patent term under the GAIN framework
Listed patents	Potential Paragraph IV challenge and litigation risk
Formulation patents	May protect specific presentations after base composition expiry
Method-of-use patents	May require a carve-out or restricted generic label

FDA approved Vabomere on August 29, 2017. The product received Qualified Infectious Disease Product designation, which provided a five-year extension of qualifying exclusivity or patent protection under the Generating Antibiotic Incentives Now Act.[3] That regulatory exclusivity period has expired.

The commercial timing now depends primarily on listed patents, patent-term adjustments, formulation claims, litigation settlements, and the feasibility of manufacturing a stable equivalent intravenous product.

When does Vabomere lose exclusivity?

Regulatory exclusivity that began with the 2017 approval is no longer the principal barrier. Patent protection is more important.

The Vabomere estate includes patents directed to the meropenem-vaborbactam combination and related beta-lactamase-inhibitor technology. Public patent records place key protection in the early 2030s, subject to patent-term adjustment, terminal disclaimers, pediatric extensions, claim scope, and Orange Book listing status.[2,4]

A competitor evaluating entry should distinguish between:

• The earliest possible ANDA filing date.
• The date of a Paragraph IV notice.
• The date litigation is filed.
• The date a court may authorize launch.
• The expiration of each enforceable claim.
• The date of any settlement-based launch license.

The earliest patent expiration does not necessarily establish the earliest commercial entry date. A generic may launch after invalidating or avoiding a patent, after obtaining a covenant not to sue, or under a settlement agreement.

Which companies are challenging Vabomere?

Vabomere is marketed in the United States by Melinta Therapeutics, an Innoviva company.[5] Publicly visible market activity has been shaped more by the difficulty of developing a stable intravenous combination product than by a broad field of branded competitors.

Potential challengers include:

• Generic injectable manufacturers with carbapenem manufacturing capability.
• Contract development and manufacturing organizations.
• Hospital-focused pharmaceutical suppliers.
• Companies with existing meropenem sterile-powder platforms.
• International manufacturers seeking regulated-market entry.

A Paragraph IV challenger would need to establish bioequivalence and pharmaceutical equivalence while demonstrating equivalent strength, quality, sterility, container performance, and labeling. The absence of a complex excipient system may simplify some aspects of equivalence, but the combination product and intravenous delivery requirements remain substantial barriers.

How strong is the Vabomere patent estate?

The estate is commercially stronger than the excipient list alone suggests.

Strengths

• Fixed-dose combination of an established carbapenem with a newer beta-lactamase inhibitor.
• Intravenous formulation with meaningful manufacturing requirements.
• Potential composition, process, formulation, and method-of-use claim layers.
• Infectious-disease regulatory incentives.
• Hospital switching costs associated with antimicrobial stewardship and susceptibility data.

Weaknesses

• The marketed excipient system is narrow and may offer limited room for broad composition claims.
• Meropenem is an established active ingredient.
• A generic may attempt to preserve the same active ingredients while using a non-infringing formulation process.
• Method-of-use enforcement can be difficult when physicians prescribe the product for overlapping infections.
• Hospital buyers may accept therapeutic substitution when pricing is materially lower.

Patent strength therefore depends more on claim breadth, validity, manufacturing know-how, and the ability to protect a stable product than on the presence of multiple excipients.

What generic entry risks exist for Vabomere?

The main generic-entry scenarios are:

Scenario	Likely commercial effect
No challenge before patent expiry	Branded sales continue until authorized entry
Paragraph IV challenge with early litigation	Litigation costs and possible launch uncertainty
Single generic launch after settlement	Moderate price erosion, with controlled competition
Multiple generic launches	Rapid price erosion and formulary substitution
Authorized generic	Greater price control but lower branded net revenue
Improved ready-to-use competitor	Potential share loss before full generic substitution

Hospital antibiotic markets are sensitive to supply reliability. A generic with lower price but unstable supply may not displace the reference product quickly. Conversely, a generic with ready-to-use packaging or longer in-use stability could compete on operational value as well as price.

What manufacturing and intellectual-property barriers affect Vabomere?

The primary manufacturing barriers are:

• Sterile production of two active ingredients in one vial.
• Consistent blend uniformity.
• Control of residual moisture after lyophilization.
• Reconstitution performance.
• Control of degradation products.
• Compatibility with infusion bags and administration sets.
• Validated aseptic processing.
• Reliable supply of vaborbactam at commercial scale.

Manufacturing know-how may remain valuable after core patents expire. A competitor that cannot reproduce the stability profile may need a different excipient or lyophilization process, which increases development time and regulatory risk.

How does Vabomere compare with meropenem alone?

Attribute	Vabomere	Meropenem alone
Active ingredients	Meropenem plus vaborbactam	Meropenem
Target	Selected infections involving susceptible beta-lactamase-producing organisms	Broad hospital bacterial infections
Excipient strategy	Combination stability with sodium carbonate buffering	Simpler single-active formulation
Infusion burden	Three-hour infusion in labeled adult regimen	Typically shorter standard infusion
Generic complexity	Combination injectable product	Mature generic market
Differentiation	Beta-lactamase inhibition and resistance-management value	Lower cost and established availability

Vabomere's commercial proposition depends on activity against organisms where meropenem alone is compromised by beta-lactamase-mediated resistance. Its value is therefore linked to microbiology, stewardship, hospital protocols, and resistance trends rather than excipient differentiation alone.[1,6]

What licensing opportunities exist around Vabomere formulation technology?

Licensing opportunities are most credible in four areas:

1. Ready-to-use delivery: A partner with a dual-chamber bag, premix platform, or automated reconstitution system could license the technology to the product owner or a generic entrant.
2. Stability enhancement: A formulation company could license a buffer, lyophilization cycle, or container system that extends refrigerated or room-temperature stability.
3. Regional manufacturing: Local sterile-injectable manufacturers could seek rights for markets where Vabomere access is limited.
4. Hospital compounding systems: Pharmacy technology companies could commercialize validated preparation workflows, provided the system does not infringe formulation or device patents.

The highest-value deal structure would likely combine formulation rights, manufacturing transfer, regulatory support, and supply commitments. A license limited to a new excipient is less attractive unless it produces a material shelf-life or administration benefit.

Key Takeaways

• Vabomere uses a deliberately minimal formulation based on meropenem, vaborbactam, and sodium carbonate.
• Sodium carbonate is central to pH control and stability but offers limited standalone differentiation.
• The strongest commercial opportunities are ready-to-use bags, extended stability, reduced-volume delivery, and pediatric-friendly presentations.
• Vabomere is an injectable small-molecule combination, so generic ANDA risk applies; biosimilar risk does not.
• FDA exclusivity from the 2017 approval has expired, leaving patents, manufacturing know-how, and formulation performance as the main barriers.
• Key patent protection extends into the early 2030s based on public records, subject to claim validity and current Orange Book status.
• A generic with superior pharmacy workflow or supply reliability could compete before broad price erosion occurs.
• Formulation and delivery patents may retain value after core composition protection weakens.

FAQs

Can Vabomere be reformulated without sodium carbonate?

A competitor could develop a different buffer system, but it would need to demonstrate equivalent stability, potency, sterility, reconstitution, and infusion compatibility. Removing sodium carbonate without replacing its functional role would create substantial stability risk.

Is Vabomere suitable for a premixed intravenous bag?

Potentially, but a premixed bag would require dedicated stability, container-closure, particulate, extractables-and-leachables, sterility, and administration-set studies. The key technical issue is maintaining meropenem and vaborbactam potency throughout the labeled storage period.

Does Vabomere have biosimilar competition?

No. Vabomere is regulated as a small-molecule drug combination. Competitive products would generally pursue an ANDA or, depending on the proposed changes, another small-molecule regulatory pathway.

What is the most defensible excipient patent opportunity for Vabomere?

The strongest opportunity is likely a defined formulation or process that produces a measurable stability or handling advantage, such as extended in-use stability, reduced degradation, faster reconstitution, or improved container compatibility.

Could a generic Vabomere use different excipients?

Yes, subject to FDA requirements and patent constraints. A generic must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable requirements for an injectable product. A different excipient system could also be designed to avoid specific formulation claims.

References

1. U.S. Food and Drug Administration. (2024). Vabomere (meropenem and vaborbactam) prescribing information. Melinta Therapeutics.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. NDA 209776.

3. U.S. Food and Drug Administration. (2017). FDA approves new antibacterial drug Vabomere. FDA Drug Safety and Availability.

4. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for meropenem-vaborbactam formulations and beta-lactamase inhibitor combinations.

5. Innoviva, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

6. Kaye, K. S., et al. (2020). Clinical and microbiologic outcomes with meropenem-vaborbactam in carbapenem-resistant Enterobacterales infections. Clinical Infectious Diseases.